Jade Biosciences JBIO EBIT

EBIT at other companies

Vertex PharmaceuticalsVRTX

$1.25B+8.3%

Travere Therapeutics, Inc.TVTX

-$36.92M+13.5%

Vera TherapeuticsVERA

-$125.13M-119%

Vor BiopharmaVOR

-$35.16M-5.6%

AnaptysBio, Inc.ANAB

-$34.64M-25.8%

Avalo TherapeuticsAVTX

-$31.52M-63.2%

FAQ

What is Jade Biosciences's EBIT?

Jade Biosciences (JBIO) reported EBIT of -$43.45M in Q1 2026.

How has Jade Biosciences's EBIT changed year-over-year?

Jade Biosciences's EBIT decreased by 85.8% year-over-year, from -$23.38M to -$43.45M.

What is the long-term trend for Jade Biosciences's EBIT?

Over 4 years (2021 to 2025), Jade Biosciences's EBIT has grown at a 49.0% compound annual growth rate (CAGR), from -$23.02M to -$113.54M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.